Dr. Diana V. Do, MD
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 557
Licensed in California since 2016, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of California, San Francisco School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
CA license C143489 (first issued 2016; current) -
Ophthalmology Physician
CA license C143489 (first issued 2016; current) · MD license D59856
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
- County of Santa Clara (1,022 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 557
- Services billed
- 2,677
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Imaging of retina | 939 | 428 |
| Established patient office or other outpatient visit, 20-29 minutes | 506 | 349 |
| Established patient office or other outpatient visit, 30-39 minutes | 332 | 107 |
| Injection of drug into eye | 271 | 80 |
| New patient office or other outpatient visit, 30-44 minutes | 30 | 30 |
| Complex removal of cataract with insertion of prosthetic lens | 29 | 23 |
| Measurement of corneal curvature and depth of eye | 18 | 18 |
| Exam of visual field with extended testing | 16 | 14 |
| New patient office or other outpatient visit, 45-59 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketorolac Tromethamine Other prescribers in Stanford, CA | 40 |
| Latanoprost Other prescribers in Stanford, CA | 37 |
| Prednisolone Acetate Other prescribers in Stanford, CA | 22 |
| Brimonidine Tartrate Other prescribers in Stanford, CA | 21 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Stanford, CA | 20 |
| Azelastine Hcl Other prescribers in Stanford, CA | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 48 payments worth $40,477 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $13,322 |
|---|---|
| Regeneron Pharmaceuticals, Inc. | $7,450 |
| Alcon Vision LLC | $5,650 |
| Ocular Therapeutix, Inc. | $4,603 |
| Harrow Eye, LLC | $2,937 |
| Astellas Pharma US Inc | $2,739 |
| Regeneron Healthcare Solutions, Inc. | $2,486 |
| AbbVie Inc. | $707 |
| Consulting Fee | $35,704 |
|---|---|
| Travel and Lodging | $2,784 |
| Food and Beverage | $1,989 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Apellis Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee | $4,344 |
| Apellis Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee Syfovre · Ophthalmology | $3,258 |
| Apellis Pharmaceuticals, Inc. Oct 3, 2025 | Consulting Fee Syfovre · Ophthalmology | $3,258 |
| Harrow Eye, LLC Mar 20, 2025 | Consulting Fee VEVYE; TRIESENCE · OPTOMETRY | $2,800 |
| Astellas Pharma US Inc Dec 9, 2025 | Consulting Fee Izervay · Ophthalmology | $2,600 |
| Regeneron Pharmaceuticals, Inc. Oct 10, 2025 | Consulting Fee EYLEA · OPHTHALMOLOGY | $2,381 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Consulting Fee EYLEA HD · OPHTHALMOLOGY | $2,210 |
| Apellis Pharmaceuticals, Inc. Jun 27, 2025 | Consulting Fee Syfovre · Ophthalmology | $2,172 |
| Ocular Therapeutix, Inc. Feb 2, 2025 | Consulting Fee | $2,000 |
| Ocular Therapeutix, Inc. Oct 4, 2025 | Consulting Fee | $2,000 |
All 27 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Dec 9, 2025 | Consulting Fee Izervay · Ophthalmology | $2,600 |
| Alcon Vision LLC Nov 6, 2025 | Consulting Fee | $500 |
| Alcon Vision LLC Oct 23, 2025 | Consulting Fee | $2,000 |
| Regeneron Pharmaceuticals, Inc. Oct 10, 2025 | Consulting Fee EYLEA · OPHTHALMOLOGY | $2,381 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Consulting Fee EYLEA HD · OPHTHALMOLOGY | $2,210 |
| Regeneron Pharmaceuticals, Inc. Oct 10, 2025 | Consulting Fee EYLEA · OPHTHALMOLOGY | $794 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Consulting Fee EYLEA HD · OPHTHALMOLOGY | $276 |
| Alcon Vision LLC Oct 9, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. Oct 4, 2025 | Consulting Fee | $2,000 |
| Apellis Pharmaceuticals, Inc. Oct 3, 2025 | Consulting Fee Syfovre · Ophthalmology | $3,258 |
| Alcon Vision LLC Sep 18, 2025 | Consulting Fee | $2,000 |
| Apellis Pharmaceuticals, Inc. Jun 27, 2025 | Consulting Fee Syfovre · Ophthalmology | $2,172 |
| Apellis Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee Syfovre · Ophthalmology | $3,258 |
| Harrow Eye, LLC Mar 20, 2025 | Consulting Fee VEVYE; TRIESENCE · OPTOMETRY | $2,800 |
| Regeneron Pharmaceuticals, Inc. Mar 14, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to LISBON, Portugal · in-kind | $437 |
| Regeneron Pharmaceuticals, Inc. Mar 14, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to LISBON, Portugal · in-kind | $435 |
| Regeneron Pharmaceuticals, Inc. Mar 14, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to LISBON, Portugal · in-kind | $435 |
| Regeneron Pharmaceuticals, Inc. Mar 14, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to STOKHOLM, Sweden · in-kind | $303 |
| Regeneron Pharmaceuticals, Inc. Mar 14, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to STOKHOLM, Sweden · in-kind | $302 |
| Regeneron Pharmaceuticals, Inc. Mar 14, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to STOKHOLM, Sweden · in-kind | $301 |
| AbbVie Inc. Feb 6, 2025 | Consulting Fee | $581 |
| Ocular Therapeutix, Inc. Feb 2, 2025 | Consulting Fee | $2,000 |
| Apellis Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee | $4,344 |
| Regeneron Pharmaceuticals, Inc. Jan 17, 2025 | Consulting Fee EYLEA HD · OPHTHALMOLOGY | $510 |
| Regeneron Pharmaceuticals, Inc. Jan 17, 2025 | Consulting Fee EYLEA HD · OPHTHALMOLOGY | $510 |
| Regeneron Pharmaceuticals, Inc. Jan 17, 2025 | Consulting Fee EYLEA HD · OPHTHALMOLOGY | $510 |
| Ocular Therapeutix, Inc. Jan 1, 2025 | Travel and Lodging travel to Hawaii, HI | $572 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $42,185 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.